FIELD: medicine.
SUBSTANCE: invention is designed to predict the risk of decrease in the efficiency of antiplatelet therapy with clopidogrel and acetylsalicylic acid preparations (ACA) in patients with ischemic heart disease (IHD) who underwent coronary arteries stenting. DNA is isolated from the venous blood of patients. Polymorphic variants T-786C of the NOS3 gene are determined by allele-specific PCR. Detection of PCR products is performed by electrophoresis method. An increased risk of a decrease in the efficiency of antiplatelet therapy with clopidogrel and acetylsalicylic acid preparations is predicted in carriers of the -786CC genotype of NOS3 gene.
EFFECT: invention allows to assess the risk of developing resistance to antiplatelet drugs and to timely adjust the therapy and improve the quality of treatment.
2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD OF DETERMINING THROMBOCYTE RESISTANCE TO DOUBLE ANTIPLATELET THERAPY IN PATIENTS WITH ISCHEMIC HEART DISEASE | 2019 |
|
RU2710272C1 |
| METHOD OF PREDICTION OF ASPIRIN RESISTANCE | 2015 |
|
RU2602664C1 |
| METHOD OF INDIVIDUAL PROGNOSIS OF CLINICAL EFFECTIVENESS OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH ACUTE CORONARY SYNDROME | 2016 |
|
RU2639772C1 |
| METHOD FOR PREVENTION OF THROMBOSIS IN INDIVIDUALS SUFFERING CARDIOVASCULAR DISEASES AND CHRONIC PAIN | 2013 |
|
RU2528904C1 |
| CARDIOPROTECTIVE, ANTIARRHYTHMIC ANTI-ISHEMIC AGENT | 2007 |
|
RU2366426C2 |
| METHOD FOR PREDICTING THE EFFECTIVENESS OF AN ANTIPLATELET THERAPY WITH THE PREPARATION "CLOPIDOGRELUM" | 2019 |
|
RU2702753C1 |
| METHOD OF DETERMINING THROMBOCYTE SENSITIVITY TO ACETYLSALICYLIC ACID | 2018 |
|
RU2699569C1 |
| METHOD OF DETERMINING ANTI-THROMBOTIC EFFECT OF ACETYLSALICYLIC ACID | 2007 |
|
RU2379684C2 |
| METHOD OF DIAGNOSING RESISTANCE TO ACETYLSALICYLIC ACID | 2009 |
|
RU2413953C1 |
| COMBINATION POSSESSING ANTIAGGREGANT, LIPID-REGULATING AND GASTROPROTECTIVE ACTIVITIES, PHARMACEUTICAL COMPOSITION | 2010 |
|
RU2453314C1 |
